---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Effect on quality measures"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Effect on quality measures. Topics: AAAAI and ACAAI urticaria measures: laboratory test overuse and antihistamine updosing underuse; Recommendation against routine extensive testing in chronic urticaria; Physician adherence to CSU guidelines in a multinational online survey of dermatologists and allergists, Novartis-funded; Physician awareness of and adherence to CSU guidelines, Genentech-funded study. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/effect-on-quality-measures"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Effect on quality measures

<a id="heading-2.1.2.13"></a>

## 2.1.2.13 Effect of Barzolvolimab on Quality Measures

<a id="topic-2.1.2.13-1"></a>

### AAAAI and ACAAI urticaria measures: laboratory test overuse and antihistamine updosing underuse

| Measure | Quoted measure title | Quoted measure description |
| --- | --- | --- |
| Urticaria Measure 1 | “Overuse: Laboratory Tests for Connective Tissue Disease” | “Percentage of patients seen at one or more visits within a 12-month period with a diagnosis of chronic urticaria/angioedema, who underwent diagnostic testing for connective tissue disease in the absence of a history or symptoms consistent with or suggestive of a connective tissue disease.” |
| Urticaria Measure 2 | “Overuse: Laboratory Tests for Food Allergy” | “Percentage of patients seen at one or more visits within a 12-month period with a diagnosis of chronic urticaria/angioedema, who underwent skin or in vitro testing for food allergies.” |
| Urticaria Measure 3 | “Overuse: Laboratory Tests for Inhalant Allergy” | “Percentage of patients seen at one or more visits within a 12-month period with a diagnosis of chronic urticaria/angioedema, who underwent skin or in vitro testing for inhalant allergens.” |
| Urticaria Measure 4 | “Overuse: Laboratory Tests for Hereditary or Acquired Angioedema” | “Percentage of patients seen at one or more visits within a 12-month period with a diagnosis of chronic urticaria with or without angioedema, who underwent diagnostic testing for a C1 inhibitor deficiency syndrome.” |
| Urticaria Measure 5 | “Underuse: Higher doses of Antihistamines” | “The proportion of patients with chronic urticaria that is uncontrolled on monotherapy with approved doses of 2nd generation antihistamines, who are advanced as tolerated to one or more of the following: higher doses of second generation antihistamines; addition of another 2nd generation antihistamine, addition of a leukotriene antagonist, addition of an H2 blocker, or addition of a 1st generation antihistamine to be taken at bedtime.” |

Source: [AAAAI Urticaria Measures Set (2015)](https://www.aaaai.org/Aaaai/media/Media-Library-PDFs/Practice%20Management/Practice%20Tools/Urticaria-Measures-Set_Final-2015_2026-7-20.pdf)

> “consensus by the AAAAI and ACAAI Joint Task Force on Quality Measures has determined that an error rate of no more than 25% is acceptable for this measure to allow for clinician discretion to evaluate atypical cases.”
> “Maintenance of Certification® Programs”

Source: [AAAAI Urticaria Measures Set (2015)](https://www.aaaai.org/Aaaai/media/Media-Library-PDFs/Practice%20Management/Practice%20Tools/Urticaria-Measures-Set_Final-2015_2026-7-20.pdf)

<a id="topic-2.1.2.13-2"></a>

### Recommendation against routine extensive testing in chronic urticaria

> “In the overwhelming majority of patients with chronic urticaria, a definite etiology is not identified.”
> “Routine extensive testing is neither cost-effective nor associated with improved clinical outcomes.”

Source: [AAAAI Choosing Wisely list](https://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Media/Choosing-WiselyT.pdf)

<a id="topic-2.1.2.13-3"></a>

### Physician adherence to CSU guidelines in a multinational online survey of dermatologists and allergists, Novartis-funded

> “This is a multinational cross-sectional online survey involving patients with CSU and CSU-treating physicians from seven countries (USA, Canada, UK, Germany, France, Italy, and Japan).”
> “Overall, 862 physicians (517 dermatologists; 345 allergists) participated in the study.”
> “Globally, 56% of physicians adhered to guidelines, 19% followed therapeutic protocols, and approximately 30% did not adhere to any guideline.”
> “This study and the journal’s Rapid Service Fees were funded by Novartis Pharma AG, Basel, Switzerland.”

Source: [Weller et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12454223/)

<a id="topic-2.1.2.13-4"></a>

### Physician awareness of and adherence to CSU guidelines, Genentech-funded study

> “Finally, some physicians are not aware of, or do not adhere to, international guidelines available for the treatment of CSU.”
> “This study was funded by Genentech, Inc, a member of the Roche Group.”

Source: [Mosnaim et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12814061/)

<a id="topic-2.1.2.13-5"></a>

### Product-specific effect on quality measures

No evidence found.

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
